Related Experiment Video
Updated: Aug 12, 2026
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
New monoclonal antibody against human cervical carcinoma with diagnostic and therapeutic potential
S R Roffler1, M H Yu, M R Chen
1Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, R.O.C.
Insights
A novel monoclonal antibody, Mab 1H10, shows high specificity for human cervical carcinoma and other tumor cells. This antibody demonstrates potential for targeted cancer therapies, particularly in cervical cancer treatment.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Development of targeted therapies for various cancers remains a critical area of research.
- Monoclonal antibodies offer specific targeting capabilities for cancer cells.
Purpose of the Study:
- To characterize a new murine monoclonal antibody, Mab 1H10, for its specificity against human tumor types.
- To evaluate the potential utility of Mab 1H10 in targeted cancer therapy, especially for cervical carcinoma.
Main Methods:
- Indirect immunofluorescence and flow cytometry were used to assess antibody reactivity with tumor cell lines.
- Immunohistochemical staining was employed to evaluate Mab 1H10 binding to patient-derived tumor tissue samples.
- Reactivity was tested against a panel of cancer cell lines and normal human tissues/cells.
Main Results:
- Mab 1H10 demonstrated significant reactivity with cervical, colorectal, and bladder carcinoma cell lines.
- The antibody also showed reactivity with melanoma and hepatocellular carcinoma cells, but less so.
- Immunohistochemical analysis confirmed binding to a substantial proportion of cervical and colorectal carcinoma tissues, as well as other cancer types, while showing no reactivity with normal tissues.
Conclusions:
- Mab 1H10 exhibits high specificity for human cervical carcinoma and other malignant cells.
- The antibody's selective binding profile suggests its potential as a valuable tool for targeted drug, toxin, or radioisotope delivery in cancer treatment, particularly for cervical carcinoma.
Abstract:
A new murine monoclonal IgG3 antibody (Mab 1H10) was developed with specificity for human cervical carcinoma and several other tumor types. Antibody reactivity against a panel of tumor cell lines was examined by indirect immunofluorescence and quantified by flow cytometry. Mab 1H10 reacted with cervical, colorectal and bladder carcinoma cells and to a lesser extent melanoma and hepatocellular carcinoma cells but did not react with human fibroblasts, lymphocytes or RBCs. Mab 1H10, as assessed by immunohistochemical staining, bound 40/97 cervical carcinoma tissue samples, 8/16 colorectal carcinoma samples as well as a population of osteogenic sarcoma and lung, ovarian and bladder carcinoma tissues. Mab 1H10 did not react with any normal tissue or cell samples tested including cervix, ovary, breast, liver, colon, bladder, lung, spleen, cerebrum, lymphocytes or RBCs. Mab 1H10 may be useful for the targeting of drugs, toxins or radioisotopes to cervical carcinoma in humans.
